Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences-Reference-Cited by-同舟云学术

Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences

Published:2010-04 Issue:4 Volume:105 Page:866-875
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Chang Lin,Tong Kenneth,Ameen Vanessa

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg201025.pdf

Reference45 articles.

1. A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.;Bardhan;Aliment Pharmacol Ther,2000

2. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomised, placebo controlled study.;Camilleri;Lancet,2000

3. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant IBS.;Camilleri;Archives Int Med,2001

4. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5-HT3-receptor antagonist.;Camilleri;Aliment Pharmacol Ther,1999

5. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.;Chey;Am J Gastroenterol,2004

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Curious Case of Colitis;Gastroenterology;2024-04

2. Randomised, placebo‐controlled trial and meta‐analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: The TRITON trial;Alimentary Pharmacology & Therapeutics;2023-03-03

3. Antimicrobial Treatments of Infectious Diarrhea;Reference Module in Biomedical Sciences;2021

4. Irritable Bowel Syndrome;Geriatric Gastroenterology;2021

5. Targeting the 5-HT system: Potential side effects;Neuropharmacology;2020-11